Design, in silico optimization, and generation of recombinant rabies virus glycoprotein: Paving the Way for Enhanced Vaccines Design, In Silico Optimization, and Generation of Recombinant Rabies Virus Glycoprotein
Iranian Journal of Pharmaceutical Sciences,
Vol. 20 No. 4 (2024),
17 Aban 2024
,
Page 387- 399
https://doi.org/10.22037/ijps.v20i4.45780
Abstract
Rabies is a fatal disease that may be transmitted from animals to humans. It is caused by a virus called rabies virus (RABV), which is a kind of RNA virus belonging to the family Rhabdoviridae and the genus Lyssavirus. Current rabies vaccines, while effective, require multiple doses for adequate protection, which presents significant financial and logistical challenges, especially in low-resource settings. Additionally, the risk of reversion to virulence in live-attenuated vaccines limits their use. This study aims to design and optimize the rabies virus glycoprotein (G protein) using in silico methods to address these challenges and develop a more effective and accessible rabies vaccine. The nucleotide sequences of the rabies virus glycoprotein were acquired from GenBank (accession number LT839616) and optimized to improve expression in Chinese Hamster Ovary (CHO) cells using bioinformatics tools. PSIPRED was employed for secondary structure prediction, and SWISS-MODEL was used for 3D structure modeling. The optimized gene was synthesized and inserted into the pcDNA3 vector. CHO cells were transfected with the recombinant plasmid, and the presence of the expressed gene was confirmed using RT-PCR and Western blot analysis. Optimizing the codons significantly enhanced the synthesis of the G protein derived from the rabies virus in CHO cells. Structural analyses confirmed the stability and proper conformation of the protein. The gene was successfully subcloned into the pcDNA3 vector, and its expression in CHO cells was verified using RT-PCR and Western blot analysis, demonstrating the effective production of the recombinant glycoprotein. This study successfully utilized bioinformatics and experimental methodologies to optimize the rabies virus G protein, demonstrating its potential as a viable vaccine candidate. The results provide a strong foundation for developing an advanced rabies vaccine that is both effective and accessible, particularly in regions where rabies remains prevalent.
- Rabies virus
- Rabies Glycoprotein
- Codon Optimaization
- Eukaryotic expression system
- Bioinformatics
- In silico methods
- Chinese Hamster Ovary (CHO) cells
How to Cite
References
Tordo, N., et al., Walking along the rabies genome: is the large GL intergenic region a remnant gene? Proceedings of the National Academy of Sciences, 1986. 83(11): p. 3914-3918.
Hosseini Heydarabadi, F., et al., A phylogenetic study of new rabies virus strains in different regions of Iran. 2020. 56: p. 361-368.
Warrell, M. and D. Warrell, Rabies and other lyssavirus diseases. The Lancet, 2004. 363(9413): p. 959-969.
Organization, W.H., WHO expert consultation on rabies: third report. Vol. 1012. 2018: World Health Organization.
Leung, A.K., H.D. Davies, and K.-L.E. Hon, Rabies: epidemiology, pathogenesis, and prophylaxis. Advances in therapy, 2007. 24: p. 1340-1347.
Hemachudha, T., et al., Human rabies: neuropathogenesis, diagnosis, and management. The Lancet Neurology, 2013. 12(5): p. 498-513.
Gan, H., et al., Global burden of rabies in 204 countries and territories, from 1990 to 2019: results from the Global Burden of Disease Study 2019. International Journal of Infectious Diseases, 2023. 126: p. 136-144.
Barbosa, T.F.S., et al., Molecular epidemiology of rabies virus isolated from different sources during a bat-transmitted human outbreak occurring in Augusto Correa municipality, Brazilian Amazon. Virology, 2008. 370(2): p. 228-236.
Bilal, A., Rabies is a zoonotic disease: a literature review. Occup. Med. Health Aff, 2021. 9(2).
Baghi, H.B., A. Bazmani, and M. Aghazadeh, The fight against rabies: the Middle East needs to step up its game. The Lancet, 2016. 388(10054): p. 1880.
Simani, S., et al., Evaluation of the effectiveness of preexposure rabies vaccination in Iran. 2004.
Wiltzer, L., et al., Interaction of rabies virus P-protein with STAT proteins is critical to lethal rabies disease. The Journal of infectious diseases, 2014. 209(11): p. 1744-1753.
Sato, G., et al., Genetic and phylogenetic analysis of glycoprotein of rabies virus isolated from several species in Brazil. Journal of Veterinary Medical Science, 2004. 66(7): p. 747-753.
Balamurugan, M., et al., In Silico Identification of Novel Ligand Molecules for Rabies Nucleoprotein using Structure-Based Method. Indian Journal Of Pharmaceutical Education And Research, 2016. 50(2): p. S140-S145.
Desmézières, E., et al., Differential stability and fusion activity of Lyssavirus glycoprotein trimers. Virus research, 2003. 91(2): p. 181-187.
Dhulipala, S. and V.N. Uversky, Looking at the Pathogenesis of the Rabies Lyssavirus Strain Pasteur Vaccins through a Prism of the Disorder-Based Bioinformatics. Biomolecules, 2022. 12(10): p. 1436.
Zhang, G., et al., Rabies virus glycoprotein is an important determinant for the induction of innate immune responses and the pathogenic mechanisms. Veterinary microbiology, 2013. 162(2-4): p. 601-613.
Farahtaj, F., et al., Natural infection with rabies virus: a histopathological and immunohistochemical study of human brains. 2019. 10(1): p. 6.
Pei, J., et al., Codon optimization of G protein enhances rabies virus-induced humoral immunity. Journal of General Virology, 2019. 100(8): p. 1222-1233.
Astray, R.M., S.A.C. Jorge, and C.A. Pereira, Rabies vaccine development by expression of recombinant viral glycoprotein. Archives of virology, 2017. 162: p. 323-332.
Zhu, S. and C. Guo, Rabies control and treatment: from prophylaxis to strategies with curative potential. Viruses, 2016. 8(11): p. 279.
Zhang, W., et al., Adjuvant activity of PCP-II, a polysaccharide from Poria cocos, on a whole killed rabies vaccine. Virus research, 2019. 270: p. 197638.
Dudek, T. and D.M. Knipe, Replication-defective viruses as vaccines and vaccine vectors. Virology, 2006. 344(1): p. 230-239.
Cox, J.H., B. Dietzschold, and L. Schneider, Rabies virus glycoprotein. II. Biological and serological characterization. Infection and immunity, 1977. 16(3): p. 754-759.
Magnan, C.N., et al., High-throughput prediction of protein antigenicity using protein microarray data. 2010. 26(23): p. 2936-2943.
Angov E., et al., Heterologous protein expression is enhanced by harmonizing the codon usage frequencies of the target gene with those of the expression host. 2008. 3(5): p. e2189.
Gustafsson, C., S. Govindarajan, and J.J.T.i.b. Minshull, Codon bias and heterologous protein expression. 2004. 22(7): p. 346-353.
Dietzschold, B., et al., Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. 1983. 80(1): p. 70-74.
Navid M.T., Comparison of the immunogenicity of two inactivated recombinant rabies viruses overexpressing the glycoprotein. 2016. 161: p. 2863-2870.
- Abstract Viewed: 197 times
- IJPS_Volume 20_Issue4_Pages 387-399 Downloaded: 100 times